Recent News

• 08.27.2025 - Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
• 08.14.2025 - Lexaria’s Phase 1b GLP-1 Study Achieves Important “Last Patient Last Visit” Milestone
• 08.06.2025 - GLP-1 “Arms Race” Broadens to Include Dozens of Companies
• 07.28.2025 - Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
• 07.23.2025 - Lexaria’s DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
• 06.23.2025 - Lexaria Reaches Patent Milestone – 50 Patents Now Granted Worldwide
• 06.11.2025 - Lexaria’s DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
• 06.05.2025 - Lexaria Attending BIO International Convention

Recent Filings

• 07.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 06.12.2025 - 8-K Current report
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities